Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) is important, significant and overlapping in nature. This review will analyze the relationship ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Incorporating chest CT imaging and respiratory symptoms into the chronic obstructive pulmonary disease (COPD) diagnostic ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Sinus congestion doesn’t have a one-size-fits-all treatment. You can try massage or antihistamines. Find other suggestions ...

Dubia: May 31 is observed as World No Tobacco Day, a worldwide campaign dedicated to raising awareness about the harmful effects of tobacco. In the UAE, officials are ramping up anti-smoking ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.